Sinclair John C, Haughton Diane E, Bracken Michael B, Horbar Jeffrey D, Soll Roger F
Department of Pediatrics, McMaster University Medical Centre, Room 3N11F, 1200 Main Street West, Hamilton, Ontario L8N 3Z5, Canada.
Clin Perinatol. 2003 Jun;30(2):285-304. doi: 10.1016/s0095-5108(03)00025-3.
A survey is reported of 113 systematic reviews of therapies in neonatology, based on 559 eligible randomized trials in total. These reviews were prepared by the CNRG and were published in the Cochrane Library, Issue 3,2001. The median number of included trials per review was 3 (range 0 to 32) and participants 207 (range 0 to 5460). Among 90 reviews with a categorical primary outcome, the median number of outcome events per review was 54 (range 1 to 1284). Among reviews finding a statistically significant benefit of treatment, the effect size was large (median relative risk 0.55, range 0.09 to 0.93). Reviews of surfactant for prevention and treatment of respiratory distress syndrome were able to detect moderate-sized treatment effects (median relative risk 0.85) because of the large number and size of trials in this field. Among many reviews finding no evidence of treatment effect, large and potentially important benefits or harms could not be excluded. Most CNRG reviews were current. There is a continuing need to prepare systematic review of therapies not yet covered and to keep an increasing number of reviews up-to-date.
本文报道了一项对113篇新生儿科治疗方法系统评价的调查，这些评价基于总共559项符合条件的随机试验。这些评价由CNRG编写，并发表在《Cochrane图书馆》2001年第3期。每项评价纳入试验的中位数为3项（范围0至32项），参与者为207名（范围0至5460名）。在90项有分类主要结局的评价中，每项评价结局事件的中位数为54个（范围1至1284个）。在发现治疗有统计学显著益处的评价中，效应量较大（中位数相对危险度为0.55，范围0.09至0.93）。由于该领域试验数量多且规模大，关于表面活性剂预防和治疗呼吸窘迫综合征的评价能够检测到中等大小的治疗效果（中位数相对危险度为0.85）。在许多未发现治疗效果证据的评价中，不能排除存在大的且可能重要的益处或危害。大多数CNRG评价是最新的。仍持续需要编写尚未涵盖的治疗方法的系统评价，并使越来越多的评价保持更新。
